{"id":456603,"date":"2021-03-12T04:11:53","date_gmt":"2021-03-12T09:11:53","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456603"},"modified":"2021-03-12T04:11:53","modified_gmt":"2021-03-12T09:11:53","slug":"nordic-nanovector-asa-financial-calendar","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/","title":{"rendered":"Nordic Nanovector ASA: Financial calendar"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">OSLO, Norway<\/span>, <span class=\"xn-chron\">March 12, 2021<\/span> \/PRNewswire\/ &#8212;<\/p>\n<p>FINANCIAL YEAR 2020<\/p>\n<ul type=\"disc\">\n<li>\n          <span class=\"xn-chron\">22.03.2021<\/span> &#8211; Extraordinary General Meeting <\/li>\n<li>\n          <span class=\"xn-chron\">26.03.2021<\/span> &#8211; Annual Report<\/li>\n<\/ul>\n<p>FINANCIAL YEAR 2021<\/p>\n<ul type=\"disc\">\n<li>\n          <span class=\"xn-chron\">28.04.2021<\/span> &#8211; Annual General Meeting <\/li>\n<li>\n          <span class=\"xn-chron\">26.05.2021<\/span> &#8211; Quarterly Report &#8211; Q1 <\/li>\n<li>\n          <span class=\"xn-chron\">27.08.2021<\/span> &#8211; Half-yearly Report <\/li>\n<li>\n          <span class=\"xn-chron\">18.11.2021<\/span> &#8211; Quarterly Report &#8211; Q3<\/li>\n<\/ul>\n<p>\n        <b>For further information, please contact:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/b>\n      <\/p>\n<p>\n        <b>IR enquiries<\/b>\n      <\/p>\n<p>Malene Brondberg, CFO<br \/>Cell: +44 7561 431 762<br \/>Email:\u00a0<a target=\"_blank\" href=\"mailto:ir@nordicnanovector.com\" rel=\"nofollow noopener noreferrer\">ir@nordicnanovector.com<\/a><\/p>\n<p>\n        <b>Media Enquiries<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Mark Swallow<\/span>\/Frazer Hall\/<span class=\"xn-person\">David Dible<\/span> (Citigate Dewe Rogerson)<br \/>Tel: +44 203 926 8535<br \/>Email:\u00a0<a target=\"_blank\" href=\"mailto:nordicnanovector@citigatedewerogerson.com\" rel=\"nofollow noopener noreferrer\">nordicnanovector@citigatedewerogerson.com<\/a><\/p>\n<p>\n        <b>About Nordic Nanovector:<\/b>\n      <\/p>\n<p>Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector&#8217;s lead clinical-stage candidate is Betalutin\u00ae, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin&#8217;s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly <span class=\"xn-money\">USD 26 billion<\/span> by 2028. Nordic Nanovector retains global marketing rights to Betalutin\u00ae and intends to actively participate in the commercialisation of Betalutin\u00ae in the US and other major markets.<\/p>\n<p>Further information can be found at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3095307-1&amp;h=4144886666&amp;u=http%3A%2F%2Fwww.nordicnanovector.com%2F&amp;a=www.nordicnanovector.com\" rel=\"nofollow noopener noreferrer\">www.nordicnanovector.com<\/a>.<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3095307-1&amp;h=3865746858&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3095307-1&amp;h=1193569507&amp;u=https%3A%2F%2Fnews.cision.com%2Fnordic-nanovector%2Fr%2Fnordic-nanovector-asa--financial-calendar%2Cc3305287&amp;a=https%3A%2F%2Fnews.cision.com%2Fnordic-nanovector%2Fr%2Fnordic-nanovector-asa--financial-calendar%2Cc3305287\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/nordic-nanovector\/r\/nordic-nanovector-asa&#8211;financial-calendar,c3305287<\/a>\n      <\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO07951&amp;sd=2021-03-12\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/nordic-nanovector-asa-financial-calendar-301246301.html\">http:\/\/www.prnewswire.com\/news-releases\/nordic-nanovector-asa-financial-calendar-301246301.html<\/a><\/p>\n<p>SOURCE  Nordic Nanovector<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO07951&amp;Transmission_Id=202103120408PR_NEWS_USPR_____IO07951&amp;DateId=20210312\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire OSLO, Norway, March 12, 2021 \/PRNewswire\/ &#8212; FINANCIAL YEAR 2020 22.03.2021 &#8211; Extraordinary General Meeting 26.03.2021 &#8211; Annual Report FINANCIAL YEAR 2021 28.04.2021 &#8211; Annual General Meeting 26.05.2021 &#8211; Quarterly Report &#8211; Q1 27.08.2021 &#8211; Half-yearly Report 18.11.2021 &#8211; Quarterly Report &#8211; Q3 For further information, please contact:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email:\u00a0ir@nordicnanovector.com Media Enquiries Mark Swallow\/Frazer Hall\/David Dible (Citigate Dewe Rogerson)Tel: +44 203 926 8535Email:\u00a0nordicnanovector@citigatedewerogerson.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector&#8217;s lead clinical-stage candidate is Betalutin\u00ae, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nordic Nanovector ASA: Financial calendar&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-456603","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nordic Nanovector ASA: Financial calendar - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nordic Nanovector ASA: Financial calendar - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire OSLO, Norway, March 12, 2021 \/PRNewswire\/ &#8212; FINANCIAL YEAR 2020 22.03.2021 &#8211; Extraordinary General Meeting 26.03.2021 &#8211; Annual Report FINANCIAL YEAR 2021 28.04.2021 &#8211; Annual General Meeting 26.05.2021 &#8211; Quarterly Report &#8211; Q1 27.08.2021 &#8211; Half-yearly Report 18.11.2021 &#8211; Quarterly Report &#8211; Q3 For further information, please contact:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email:\u00a0ir@nordicnanovector.com Media Enquiries Mark Swallow\/Frazer Hall\/David Dible (Citigate Dewe Rogerson)Tel: +44 203 926 8535Email:\u00a0nordicnanovector@citigatedewerogerson.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector&#8217;s lead clinical-stage candidate is Betalutin\u00ae, &hellip; Continue reading &quot;Nordic Nanovector ASA: Financial calendar&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-12T09:11:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO07951&amp;sd=2021-03-12\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nordic Nanovector ASA: Financial calendar\",\"datePublished\":\"2021-03-12T09:11:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/\"},\"wordCount\":220,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO07951&amp;sd=2021-03-12\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/\",\"name\":\"Nordic Nanovector ASA: Financial calendar - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO07951&amp;sd=2021-03-12\",\"datePublished\":\"2021-03-12T09:11:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO07951&amp;sd=2021-03-12\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO07951&amp;sd=2021-03-12\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nordic-nanovector-asa-financial-calendar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nordic Nanovector ASA: Financial calendar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nordic Nanovector ASA: Financial calendar - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/","og_locale":"en_US","og_type":"article","og_title":"Nordic Nanovector ASA: Financial calendar - Market Newsdesk","og_description":"PR Newswire OSLO, Norway, March 12, 2021 \/PRNewswire\/ &#8212; FINANCIAL YEAR 2020 22.03.2021 &#8211; Extraordinary General Meeting 26.03.2021 &#8211; Annual Report FINANCIAL YEAR 2021 28.04.2021 &#8211; Annual General Meeting 26.05.2021 &#8211; Quarterly Report &#8211; Q1 27.08.2021 &#8211; Half-yearly Report 18.11.2021 &#8211; Quarterly Report &#8211; Q3 For further information, please contact:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email:\u00a0ir@nordicnanovector.com Media Enquiries Mark Swallow\/Frazer Hall\/David Dible (Citigate Dewe Rogerson)Tel: +44 203 926 8535Email:\u00a0nordicnanovector@citigatedewerogerson.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector&#8217;s lead clinical-stage candidate is Betalutin\u00ae, &hellip; Continue reading \"Nordic Nanovector ASA: Financial calendar\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-12T09:11:53+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO07951&amp;sd=2021-03-12","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nordic Nanovector ASA: Financial calendar","datePublished":"2021-03-12T09:11:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/"},"wordCount":220,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO07951&amp;sd=2021-03-12","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/","name":"Nordic Nanovector ASA: Financial calendar - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO07951&amp;sd=2021-03-12","datePublished":"2021-03-12T09:11:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO07951&amp;sd=2021-03-12","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO07951&amp;sd=2021-03-12"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nordic-nanovector-asa-financial-calendar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nordic Nanovector ASA: Financial calendar"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=456603"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456603\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=456603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=456603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=456603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}